Xiya Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiya Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Hanzhe Zhang
National Clinical Research Center for Women's Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
1 shared publication- Jiazhen Chang
National Clinical Research Center for Women's Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
1 shared publication Kaili Yin
National Clinical Research Center for Women's Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
1 shared publicationMengmeng Li
National Clinical Research Center for Women's Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
1 shared publicationNa Hao
National Clinical Research Center for Women's Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
1 shared publication- Qingwei Qi
Department of Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Wiley in Prenatal Diagnosis
Development of a High‐Throughput Microarray Platform for Rapid, Low‐Cost Expanded Carrier Screening
Objective: To develop a customized expanded carrier screening (ECS) solution for 8271 variants of 265 genes. Based on a microarray platform, this solution demonstrates comparable accuracy to next‐generation sequencing (NGS) platform; however, it has a lower cost, a faster speed, and a simplified data—analysis process. Method: A dedicated panel composed of 8271 variants of 265 high—priority genes was developed for custom microarray fabrication. To test the performance of the custom microarray, we selected 1051 blood samples from an NGS‐based ECS project to conduct a blind test. The evaluation indicators include sensitivity, specificity and positive predictive value. Results: 582 variants were identified in 69 genes. The concordance between the microarray platform and NGS platform results reaches 99.5%. The microarray demonstrated high sensitivity (99.8%) and specificity (99.8%), showing excellent performance in both positive and negative samples. The microarray platform reduces testing cycles to 3–4 days and lowers costs by 94%–96%. Conclusion: This study confirms that microarray‐based carrier screening is a reliable, cost‐effective, and timely alternative to NGS, and it is especially suitable for large‐scale population screening.
- 9 July 2026
- Published by Wiley in Prenatal Diagnosis
Open AccessDevelopment of a High‐Throughput Microarray Platform for Rapid, Low‐Cost Expanded Carrier Screening
Objective: To develop a customized expanded carrier screening (ECS) solution for 8271 variants of 265 genes. Based on a microarray platform, this solution demonstrates comparable accuracy to next‐generation sequencing (NGS) platform; however, it has a lower cost, a faster speed, and a simplified data—analysis process. Method: A dedicated panel composed of 8271 variants of 265 high—priority genes was developed for custom microarray fabrication. To test the performance of the custom microarray, we selected 1051 blood samples from an NGS‐based ECS project to conduct a blind test. The evaluation indicators include sensitivity, specificity and positive predictive value. Results: 582 variants were identified in 69 genes. The concordance between the microarray platform and NGS platform results reaches 99.5%. The microarray demonstrated high sensitivity (99.8%) and specificity (99.8%), showing excellent performance in both positive and negative samples. The microarray platform reduces testing cycles to 3–4 days and lowers costs by 94%–96%. Conclusion: This study confirms that microarray‐based carrier screening is a reliable, cost‐effective, and timely alternative to NGS, and it is especially suitable for large‐scale population screening.